Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamibarotene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB known ✓ | P10826 | 10/20 | 1.00 |
| ▸ | RARA known ✓ | P10276 | 8/20 | 1.00 |
| ▸ | RARG | P13631 | 10/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | BLVRB | P30043 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.84 |
| ▸ | TSHR | P16473 | 1/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.84 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.74 |
| ▸ | RXRA | P19793 | 11/20 | 0.62 |
| ▸ | RXRB | P28702 | 9/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamibarotene SCHEMBL29373818 | 1.00 | RARB (1.00) | RARBRARGRARACYP26A1CYP3A4 | |
| Tamibarotene SCHEMBL21055743 | 0.99 | RARB (0.97) | RARBRARGRARACYP26A1CYP3A4 | |
| Tamibarotene SCHEMBL21274219 | 0.92 | RARB (0.85) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL726740 | 0.91 | RARB (1.00) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL29355626 | 0.91 | RARB (1.00) | RARBRARGRARACYP26A1CYP3A4 | |
| Tamibarotene SCHEMBL21274122 | 0.91 | RARB (0.83) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL22872722 | 0.91 | RARB (0.83) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL17832980 | 0.91 | RARB (0.83) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8461601 | 0.90 | CYP26A1 (0.82) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL1615110 | 0.89 | RARA (0.80) | RARBRARGRARACYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5276 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745155-A1 | POWDER CONTAINING PARTICLES OF GELATIN DERIVATIVE AND APPLICATION OF SAME IN MEDICAL TREATMENT | National Institute for Materials Science (JP) | 2026-05-20 | — | — | EP | claimed |
| EP-4744657-A1 | THERAPEUTIC AGENT FOR HUMAN GRAFT VERSUS HOST DISEASE AND COMBINATION THEREOF | National University Corporation Okayama University (JP) | 2026-05-20 | — | — | EP | claimed |
| US-20260124164-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | KYOTO UNIVERSITY (JP) | 2026-05-07 | — | — | US | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12589189-B2 | Use of retinoic acid receptor (RAR) agonists for reversing, preventing, or delaying calcification of aortic valve | INSERM (INSTITUTE NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE) (FR) | 2026-03-31 | — | — | US | claimed |
| EP-4037672-B1 | RETINOIC ACID RECEPTOR (RAR) AGONISTS FOR REVERSING, PREVENTING, OR DELAYING CALCIFICATION OF AORTIC VALVE | INST NAT SANTE RECH MED (FR) | 2026-03-11 | — | — | EP | claimed |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | AMPEL BIOSOLUTIONS, LLC (US) | 2026-02-10 | — | — | US | claimed |
| US-12521358-B2 | Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent | RAQUALIA PHARMA INC. (JP) | 2026-01-13 | — | — | US | claimed |
| US-12514834-B2 | Pharmaceutical composition for treating and/or preventing renal cystic ciliopathy | KYOTO UNIVERSITY (JP) | 2026-01-06 | — | — | US | claimed |
| US-20260000697-A1 | COMBINATION FORMULATION OF CEDAZURIDINE | OTSUKA PHARMA CO LTD (JP) | 2026-01-01 | — | — | US | claimed |
| EP-0478787-B1 | NOVEL PROCESS FOR PRODUCING BENZOIC ACID DERIVATIVE | SHIONOGI & CO (JP) | 1994-12-21 | — | — | EP | claimed |
| EP-0625045-A1 | METHODS OF TREATING INFLAMMATORY DERMATOSES | Kligman, Albert M. (US) | 1994-11-23 | — | — | EP | claimed |
| EP-0619116-A2 | Use of synthetic retinoids for osteopathy | HOECHST JAPAN LIMITED (JP) | 1994-10-12 | — | — | EP | claimed |
| EP-0465343-B1 | Pharmaceutical or cosmetical composition comprising a retinoid and a sterol in association | CIRD GALDERMA (FR) | 1994-06-15 | — | — | EP | claimed |
| WO-1993015740-A1 | METHODS OF TREATING INFLAMMATORY DERMATOSES | KLIGMAN ALBERT M (US) | 1993-08-19 | — | — | WO | claimed |
| US-5214202-A | Retinoid activity | SHIONOGI & CO., LTD. (JP) | 1993-05-25 | — | — | US | claimed |
| EP-0478787-A1 | NOVEL PROCESS FOR PRODUCING BENZOIC ACID DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 1992-04-08 | — | — | EP | claimed |
| EP-0170105-B1 | BENZOIC ACID DERIVATIVES | Shudo, Koichi, Prof. Dr. (JP) | 1990-10-17 | — | — | EP | claimed |
| US-4703110-A | Benzoic acid derivatives having a para substituent which is a substituted phenyl group connected by a linking radical; useful in neoplastic cell differentiation and diagnosis | Shudo, Koichi (JP) | 1987-10-27 | — | — | US | claimed |
| EP-0170105-A2 | Benzoic acid derivatives | Shudo, Koichi, Prof. Dr. (JP) | 1986-02-05 | — | — | EP | claimed |